Bookmark and Share
BioAssay: AID 743473

Late stage assay provider QFRET-based biochemical high throughput dose response assay to counterscreen inhibitors of ADAM10 and ADAM17 against metalloproteases MMP1, MMP2, MMP8, MMP9, MMP10, MMP13, MMP14, Meprin A, and Meprin B

Name: Late stage assay provider QFRET-based biochemical high throughput dose response assay to counterscreen inhibitors of ADAM10 and 17 against metalloproteases MMP1, MMP2, MMP8, MMP9, MMP10, MMP13, MMP14, Meprin A, and Meprin B. ..more
_
   
 Tested Compounds
 Tested Compounds
All(4)
 
 
 Tested Substances
 Tested Substances
All(4)
 
 
 Related BioAssays
 Related BioAssays
AID: 743473
Data Source: The Scripps Research Institute Molecular Screening Center (MMP_INH_QFRET_384_3XIC50)
BioAssay Type: Panel, Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2014-04-14
Hold-until Date: 2015-04-10
Modify Date: 2015-04-10

Data Table ( Complete ):           View All Data
Tested Compounds:
Related Experiments
AIDNameTypeComment
720582QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM10.Screeningdepositor-specified cross reference: Primary Assay (ADAM10 INH in singlicate)
720583Summary of a probe development effort to identify exosite inhibitors of ADAM10Summarydepositor-specified cross reference: Summary
743208QFRET-based biochemical high throughput confirmation assay to identify exosite inhibitors of ADAM10.Screeningdepositor-specified cross reference: Confirmation Assay (ADAM10 INH in triplicate)
743214Counterscreen for exosite inhibitors of ADAM10: QFRET-based biochemical high throughput screening assay to identify inhibitors of ADAM17Screeningdepositor-specified cross reference: Counterscreen Assay (ADAM17 INH in triplicate )
743253Counterscreen for exosite inhibitors of ADAM10: QFRET-based biochemical high throughput dose response assay to identify inhibitors of ADAM17Confirmatorydepositor-specified cross reference: Counterscreen Assay (ADAM17 INH dose response )
743254QFRET-based biochemical high throughput dose response assay to identify exosite inhibitors of ADAM10.Confirmatorydepositor-specified cross reference: Dose response Assay (ADAM10 INH)
743338Late stage QFRET-based biochemical high throughput dose response assay to identify exosite inhibitors of ADAM10.Confirmatorydepositor-specified cross reference: Late stage Dose response Assay (ADAM10 INH)
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: Torrey Pines Institute for Molecular Sciences (TPIMS)
Assay Provider: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS)
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R03 DA033985-01
Grant Proposal PI: Dmitriy Minond, Torrey Pines Institute for Molecular Sciences (TPIMS)
External Assay ID: MMP_INH_QFRET_384_3XIC50

Name: Late stage assay provider QFRET-based biochemical high throughput dose response assay to counterscreen inhibitors of ADAM10 and 17 against metalloproteases MMP1, MMP2, MMP8, MMP9, MMP10, MMP13, MMP14, Meprin A, and Meprin B.

Description:

Approximately 20-30% of breast cancer patients have tumors that over-express human epidermal growth factor receptor (HER2), which confers an aggressive tumor phenotype and poor prognosis [1-3]. A Disintegrin and Metalloprotease (ADAM) proteases are responsible for amplification of HER2 signaling due to either cleavage of its extracellular domain or release of HER2 ligands, which leads to proliferation and inhibition of apoptosis [4, 5]. ADAM proteases implicated in amplification of HER2 signaling [6, 7] are ADAM10 [8, 9] and 17 [10, 11]; therefore, inhibition of these proteases represents a viable approach to the abrogation of HER2 signaling in breast cancer. The specific aims of this proposal, therefore, will focus on (1) screening of the MLPCN library for inhibitors that interact with exosites of ADAM10 and 17, and (2) medicinal chemistry optimization of initial leads in order to develop molecular probes of ADAM10 and 17. Our laboratory is uniquely positioned to achieve these goals due to expertise in development of exosite-binding inhibitors and probes, HTS, and biochemistry of proteases. We will also collaborate with experts in the fields of peptide synthesis, HTS, and medicinal chemistry. The successful completion of the Aims of this proposal will lead to a discovery of novel, potent, and selective small molecule probes for ADAM10 and 17[12]. Using these selective molecular probes alone or in combination with other tools, such as siRNA, antibodies, and other small molecule inhibitors, the researchers will be able to study contributions not only of individual members of the ADAM protease family, but also the interplay of ADAM protease-controlled pathways with other pathways implicated in the progression of breast cancer [13-15].

References:

1. CDC, United States Cancer Statistics: Incidence and Mortality Web-based Report: 1999-2007 Cancer Incidence and Mortality Data. 2010, Department of Health and Human Services: Atlanta.
2. Steger, G.G., J. Abrahamova, F. Bacanu, S. Brincat, A. Brize, A. Cesas, T. Cufer, M. Dank, R. Duchnowska, A. Eniu, J. Jassem, Z. Kahan, E. Matos, P. Padrik, S. Plate, H. Pokker, G. Purkalne, C. Timcheva, V. Tzekova, R. Vyzula, and C.C. Zielinski, Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wien Klin Wochenschr, 2010. 122(11-12): p. 368-79.
3. Barros, F.F., D.G. Powe, I.O. Ellis, and A.R. Green, Understanding the HER family in breast cancer: interaction with ligands, dimerization and treatments. Histopathology, 2010. 56(5): p. 560-72.
4. Klein, T. and R. Bischoff, Active metalloproteases of the A Disintegrin and Metalloprotease (ADAM) family: biological function and structure. J Proteome Res, 2011. 10(1): p. 17-33.
5. Mazzocca, A., G. Giannelli, and S. Antonaci, Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link? Biochim Biophys Acta, 2010. 1806(1): p. 74-81.
6. Gijsen, M., P. King, T. Perera, P. Parker, B. Larijani, A. Harris, and A. Kong, Upregulation of ADAM proteases and HER ligands through a feedback loop mediates acquired resistance to trastuzumab in HER2-amplified breast cancer. Breast Cancer Res, 2010. 12 Suppl 1: p. O2.
7. Blobel, C.P., ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol, 2005. 6(1): p. 32-43.
8. Gibb, D.R., S.J. Saleem, N.S. Chaimowitz, J. Mathews, and D.H. Conrad, The emergence of ADAM10 as a regulator of lymphocyte development and autoimmunity. Mol Immunol, 2011. 48(11): p. 1319-27.
9. Endres, K. and F. Fahrenholz, Upregulation of the alpha-secretase ADAM10--risk or reason for hope? FEBS J, 2010. 277(7): p. 1585-96.
10. Scheller, J., A. Chalaris, C. Garbers, and S. Rose-John, ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol, 2011. 32(8): p. 380-7.
11. Gooz, M., ADAM-17: the enzyme that does it all. Crit Rev Biochem Mol Biol, 2010. 45(2): p. 146-69.
12. Sinnathamby, G., J. Zerfass, J. Hafner, P. Block, Z. Nickens, A. Hobeika, A.A. Secord, H.K. Lyerly, M.A. Morse, and R. Philip, ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. Clin Exp Immunol, 2011. 163(3): p. 324-32.
13. Duffy, M.J., M. Mullooly, N. O'Donovan, S. Sukor, J. Crown, A. Pierce, and P.M. McGowan, The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer? Clin Proteomics, 2011. 8(1): p. 9.
14. Gijsen, M., P. King, T. Perera, P.J. Parker, A.L. Harris, B. Larijani, and A. Kong, HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol, 2010. 8(12): p. e1000563.
15. Liu, X., J.S. Fridman, Q. Wang, E. Caulder, G. Yang, M. Covington, C. Liu, C. Marando, J. Zhuo, Y. Li, W. Yao, K. Vaddi, R.C. Newton, P.A. Scherle, and S.M. Friedman, Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol Ther, 2006. 5(6): p. 648-56.

Keywords:

Assay provider, late stage, powders, Dose Response, dose, triplicate, dilution, biochemical, endpoint, exosite, ADAM, ADAM10, ADAM17, metalloprotease, MMP1, MMP2, MMP8, MMP9, MMP10, MMP13, MMP14, meprin A, mesprin B, counterscreen, protease, enzyme, fluorescence, quench, QFRET, FRET, binding, cancer, 384, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Panel Information
Panel Assay with Multiple Targets/Outcomes
    Data Table(All)Show more
PID§NameSubstancePanel TargetsDescriptionAdditional Information
ActiveInactive
1Inhibition of MMP1 [gi:119587435]
Taxonomy id: 9606
Gene id: 4312
2Inhibition of MMP2 [gi:51831776]
Taxonomy id: 9606
Gene id: 4313
3Inhibition of MMP8 [gi:119587431]
Taxonomy id: 9606
Gene id: 4317
4Inhibition of MMP9 [gi:119596182]
Taxonomy id: 9606
Gene id: 4318
5Inhibition of MMP10 [gi:119587433]
Taxonomy id: 9606
Gene id: 4319
6Inhibition of MMP13 [gi:51895762]
Taxonomy id: 9606
Gene id: 4322
7Inhibition of MMP14 [gi:408684256]
Taxonomy id: 9606
Gene id: 4323
8Inhibition of Meprin A [gi:219520038]
Taxonomy id: 9606
Gene id: 4224
9Inhibition of Meprin B [gi:223460866]
Taxonomy id: 9606
Gene id: 4225

§ Panel component ID.
Protocol
Assay Overview:
The purpose of this assay is to counterscreen compounds that potentially inhibit ADAM10 and 17 against a series of metalloproteases from different families. This assay employs a fluorophore and quencher pair. F =MCA, Q = DNP quencher. When intact, MCA emission at 394nm is quenched by DNP via fluorescence resonance energy transfer. Upon cleavage of the scissile bond (G~L) by MMP-1 protease, the distance between fluorophore and quencher increases resulting in fluorescence increase at 394nm. Compounds are tested in triplicate using a 10-point, 1:3 dilution series starting at a nominal concentration of 100 uM.

Protocol Summary:
Prior to the start of the assay, a 1.2X solution of each metalloprotease in Assay Buffer (50mM Tricine, 50mM NaCl, 10mM CaCl2, 0.05% Brij-35, pH 7.5) is prepared as follows: ASSAY 1: MMP1 (3 nM); ASSAY2: MMP2 (3 nM); ASSAY 3: MMP8 (2 nM); ASSAY 4: MMP9 (2 nM); ASSAY 5: MMP10 (4 nM); ASSAY 6: MMP13 (2.5 nM); ASSAY 7: MMP14 (2 nM); ASSAY 8: Meprin A (2 nM); ASSAY 9: Meprin B (0.06 nM). 8.0 microliters 1.2X metalloprotease enzyme are dispensed into 384 microtiter plates. Compounds are added to plate and incubated for 30 minutes at 25 degrees Celsius. The assay is started by dispensing 2.0 microliter of 5X ES10 substrate (50 uM in Assay Buffer) to appropriate wells for ASSAYS 1, 2, 3, 4, 5, 6, and 7; 2.0 microliter of 5X (mca)-YVADAPK-(K-?-dnp) substrate (50 uM in Assay Buffer) to appropriate wells for ASSAY 8; or 2.0 microliter of 5X (mca)-EDEDED-(K-?-dnp) substrate (50 uM in Assay Buffer) to appropriate wells for ASSAY 9. Plates are centrifuged and after 1 hour of incubation at 25 degrees Celsius, fluorescence is measured (excitation = 324nm, emission = 394nm).

The % inhibition for each well was then calculated as follows:

%_Inhibition = ( RFU_Test_Compound - MedianRFU_Low_Control ) / ( MedianRFU_High_Control - MedianRFU_Low_Control ) * 100

Where:

Test_Compound is defined as wells containing test compound.
High_Control is defined as wells treated with 1 micromolar Marimastat
Low_Control is defined as wells containing DMSO.

For each test compound, percent inhibition was plotted against compound concentration. A four parameter equation describing a sigmoidal dose-response curve was then fitted with adjustable baseline using GraphPad Prizm software. The reported IC50 values were generated from fitted curves by solving for the X-intercept value at the 50% activation level of the Y-intercept value. In cases where the highest concentration tested (i.e.112.5 uM) did not result in greater than 50% activation, the IC50 was determined manually as greater than 112.5 uM.

PubChem Activity Outcome and Score:

Compounds with an IC50 greater than 10 uM in all assays were considered inactive. Compounds with an IC50 equal to or less than 10 uM in one or more assays were considered active.

List of Reagents:

MMP-1 enzyme (R&D Systems, part # 901-MP-010)
MMP-2 enzyme (R&D Systems, part # 902-MP-010 )
MMP-8 enzyme (R&D Systems, part # 908-MP-010)
MMP-9 enzyme (R&D Systems, part # 911-MP-010)
MMP-10 enzyme (R&D Systems, part # 910-MP-010 )
MMP-13 enzyme (R&D Systems, part # 511-MM-010)
MMP-14 enzyme (R&D Systems, part # 918-MP-010)
Meprin A enzyme (provided by Dr. Christoph Becker-Pauly, University of Kiel, Germany)
(mca)-YVADAPK-(K-?-dnp) substrate (provided by Dr. Christoph Becker-Pauly, University of Kiel, Germany)
Meprin B enzyme (provided by Dr. Christoph Becker-Pauly, University of Kiel, Germany)
(mca)-EDEDED-(K-?-dnp) substrate (provided by Dr. Christoph Becker-Pauly, University of Kiel, Germany)
ES010 peptide substrate (R&D Systems, part # ES010)
0.5M HEPES solution, pH7.5 (Teknova, part #101319-900)
Brij-35 (Sigma-Aldrich, part # P1254)
384 well plate (Nunc 264706)
Comment
This assay was run by the Assay Provider with purchased powder compounds.
Categorized Comment - additional comments and annotations
From BioAssay Depositor:
Assay: CurveFit [1]: Equation: = [Bottom {MMP1}] + ( [Top {MMP1}] - [Bottom {MMP1}] ) / ( 1 + 10 ^ ( ( Log10( [Inflection Point Concentration {MMP1}] * 10^-6) - Log10( [Concentration] * 10^-6) ) * [Hill Slope {MMP1}] ) )
Assay: CurveFit [2]: Equation: = [Bottom {MMP2}] + ( [Top {MMP2}] - [Bottom {MMP2}] ) / ( 1 + 10 ^ ( ( Log10( [Inflection Point Concentration {MMP2}] * 10^-6) - Log10( [Concentration] * 10^-6) ) * [Hill Slope {MMP2}] ) )
Assay: CurveFit [3]: Equation: = [Bottom {MMP8}] + ( [Top {MMP8}] - [Bottom {MMP8}] ) / ( 1 + 10 ^ ( ( Log10( [Inflection Point Concentration {MMP8}] * 10^-6) - Log10( [Concentration] * 10^-6) ) * [Hill Slope {MMP8}] ) )
Assay: Dictionary: Version: 0.1
Assay: CurveFit [4]: Equation: = [Bottom {MMP9}] + ( [Top {MMP9}] - [Bottom {MMP9}] ) / ( 1 + 10 ^ ( ( Log10( [Inflection Point Concentration {MMP9}] * 10^-6) - Log10( [Concentration] * 10^-6) ) * [Hill Slope {MMP9}] ) )
Assay: CurveFit [5]: Equation: = [Bottom {MMP10}] + ( [Top {MMP10}] - [Bottom {MMP10}] ) / ( 1 + 10 ^ ( ( Log10( [Inflection Point Concentration {MMP10}] * 10^-6) - Log10( [Concentration] * 10^-6) ) * [Hill Slope {MMP10}] ) )
Assay: CurveFit [6]: Equation: = [Bottom {MMP13}] + ( [Top {MMP13}] - [Bottom {MMP13}] ) / ( 1 + 10 ^ ( ( Log10( [Inflection Point Concentration {MMP13}] * 10^-6) - Log10( [Concentration] * 10^-6) ) * [Hill Slope {MMP13}] ) )
Assay: CurveFit [7]: Equation: = [Bottom {MMP14}] + ( [Top {MMP14}] - [Bottom {MMP14}] ) / ( 1 + 10 ^ ( ( Log10( [Inflection Point Concentration {MMP14}] * 10^-6) - Log10( [Concentration] * 10^-6) ) * [Hill Slope {MMP14}] ) )
Assay: CurveFit [8]: Equation: = [Bottom {Meprin A}] + ( [Top {Meprin A}] - [Bottom {Meprin A}] ) / ( 1 + 10 ^ ( ( Log10( [Inflection Point Concentration {Meprin A}] * 10^-6) - Log10( [Concentration] * 10^-6) ) * [Hill Slope {Meprin A}] ) )
Assay: CurveFit [9]: Equation: = [Bottom {Meprin B}] + ( [Top {Meprin B}] - [Bottom {Meprin B}] ) / ( 1 + 10 ^ ( ( Log10( [Inflection Point Concentration {Meprin B}] * 10^-6) - Log10( [Concentration] * 10^-6) ) * [Hill Slope {Meprin B}] ) )
Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1Qualifier {MMP1}Inhibition Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.1String
2IC50 {MMP1}*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) molar.1FloatμM
3Top {MMP1}The maximal or asymptotic response above the baseline as concentration increases without bound.1Float
4Bottom {MMP1}Adjustable baseline of the curve fit, minimal response value.1Float
5Hill Slope {MMP1}The variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.1Float
6Inflection Point Concentration {MMP1}The concentration value for the inflection point of the curve.1FloatμM
7Inhibition at 112.5 uM {MMP1} {1} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {1}1Float%
8Inhibition at 112.5 uM {MMP1} {2} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {2}1Float%
9Inhibition at 112.5 uM {MMP1} {3} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {3}1Float%
10Inhibition at 37.5 uM {MMP1} {1} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {1}1Float%
11Inhibition at 37.5 uM {MMP1} {2} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {2}1Float%
12Inhibition at 37.5 uM {MMP1} {3} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {3}1Float%
13Inhibition at 12.5 uM {MMP1} {1} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {1}1Float%
14Inhibition at 12.5 uM {MMP1} {2} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {2}1Float%
15Inhibition at 12.5 uM {MMP1} {3} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {3}1Float%
16Inhibition at 4.2 uM {MMP1} {1} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {1}1Float%
17Inhibition at 4.2 uM {MMP1} {2} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {2}1Float%
18Inhibition at 4.2 uM {MMP1} {3} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {3}1Float%
19Inhibition at 1.4 uM {MMP1} {1} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {1}1Float%
20Inhibition at 1.4 uM {MMP1} {2} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {2}1Float%
21Inhibition at 1.4 uM {MMP1} {3} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {3}1Float%
22Inhibition at 0.46 uM {MMP1} {1} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {1}1Float%
23Inhibition at 0.46 uM {MMP1} {2} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {2}1Float%
24Inhibition at 0.46 uM {MMP1} {3} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {3}1Float%
25Inhibition at 0.15 uM {MMP1} {1} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {1}1Float%
26Inhibition at 0.15 uM {MMP1} {2} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {2}1Float%
27Inhibition at 0.15 uM {MMP1} {3} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {3}1Float%
28Inhibition at 0.051 uM {MMP1} {1} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {1}1Float%
29Inhibition at 0.051 uM {MMP1} {2} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {2}1Float%
30Inhibition at 0.051 uM {MMP1} {3} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {3}1Float%
31Inhibition at 0.017 uM {MMP1} {1} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {1}1Float%
32Inhibition at 0.017 uM {MMP1} {2} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {2}1Float%
33Inhibition at 0.017 uM {MMP1} {3} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {3}1Float%
34Inhibition at 0.0057 uM {MMP1} {1} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {1}1Float%
35Inhibition at 0.0057 uM {MMP1} {2} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {2}1Float%
36Inhibition at 0.0057 uM {MMP1} {3} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {3}1Float%
37Qualifier {MMP2}Inhibition Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.2String
38IC50 {MMP2}*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) molar.2FloatμM
39Top {MMP2}The maximal or asymptotic response above the baseline as concentration increases without bound.2Float
40Bottom {MMP2}Adjustable baseline of the curve fit, minimal response value.2Float
41Hill Slope {MMP2}The variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.2Float
42Inflection Point Concentration {MMP2}The concentration value for the inflection point of the curve.2FloatμM
43Inhibition at 112.5 uM {MMP2} {1} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {1}2Float%
44Inhibition at 112.5 uM {MMP2} {2} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {2}2Float%
45Inhibition at 112.5 uM {MMP2} {3} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {3}2Float%
46Inhibition at 37.5 uM {MMP2} {1} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {1}2Float%
47Inhibition at 37.5 uM {MMP2} {2} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {2}2Float%
48Inhibition at 37.5 uM {MMP2} {3} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {3}2Float%
49Inhibition at 12.5 uM {MMP2} {1} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {1}2Float%
50Inhibition at 12.5 uM {MMP2} {2} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {2}2Float%
51Inhibition at 12.5 uM {MMP2} {3} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {3}2Float%
52Inhibition at 4.2 uM {MMP2} {1} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {1}2Float%
53Inhibition at 4.2 uM {MMP2} {2} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {2}2Float%
54Inhibition at 4.2 uM {MMP2} {3} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {3}2Float%
55Inhibition at 1.4 uM {MMP2} {1} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {1}2Float%
56Inhibition at 1.4 uM {MMP2} {2} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {2}2Float%
57Inhibition at 1.4 uM {MMP2} {3} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {3}2Float%
58Inhibition at 0.46 uM {MMP2} {1} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {1}2Float%
59Inhibition at 0.46 uM {MMP2} {2} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {2}2Float%
60Inhibition at 0.46 uM {MMP2} {3} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {3}2Float%
61Inhibition at 0.15 uM {MMP2} {1} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {1}2Float%
62Inhibition at 0.15 uM {MMP2} {2} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {2}2Float%
63Inhibition at 0.15 uM {MMP2} {3} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {3}2Float%
64Inhibition at 0.051 uM {MMP2} {1} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {1}2Float%
65Inhibition at 0.051 uM {MMP2} {2} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {2}2Float%
66Inhibition at 0.051 uM {MMP2} {3} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {3}2Float%
67Inhibition at 0.017 uM {MMP2} {1} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {1}2Float%
68Inhibition at 0.017 uM {MMP2} {2} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {2}2Float%
69Inhibition at 0.017 uM {MMP2} {3} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {3}2Float%
70Inhibition at 0.0057 uM {MMP2} {1} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {1}2Float%
71Inhibition at 0.0057 uM {MMP2} {2} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {2}2Float%
72Inhibition at 0.0057 uM {MMP2} {3} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {3}2Float%
73Qualifier {MMP8}Inhibition Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.3String
74IC50 {MMP8}*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) molar.3FloatμM
75Top {MMP8}The maximal or asymptotic response above the baseline as concentration increases without bound.3Float
76Bottom {MMP8}Adjustable baseline of the curve fit, minimal response value.3Float
77Hill Slope {MMP8}The variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.3Float
78Inflection Point Concentration {MMP8}The concentration value for the inflection point of the curve.3Float
79Inhibition at 112.5 uM {MMP8} {1} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {1}3Float%
80Inhibition at 112.5 uM {MMP8} {2} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {2}3Float%
81Inhibition at 112.5 uM {MMP8} {3} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {3}3Float%
82Inhibition at 37.5 uM {MMP8} {1} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {1}3Float%
83Inhibition at 37.5 uM {MMP8} {2} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {2}3Float%
84Inhibition at 37.5 uM {MMP8} {3} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {3}3Float%
85Inhibition at 12.5 uM {MMP8} {1} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {1}3Float%
86Inhibition at 12.5 uM {MMP8} {2} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {2}3Float%
87Inhibition at 12.5 uM {MMP8} {3} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {3}3Float%
88Inhibition at 4.2 uM {MMP8} {1} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {1}3Float%
89Inhibition at 4.2 uM {MMP8} {2} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {2}3Float%
90Inhibition at 4.2 uM {MMP8} {3} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {3}3Float%
91Inhibition at 1.4 uM {MMP8} {1} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {1}3Float%
92Inhibition at 1.4 uM {MMP8} {2} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {2}3Float%
93Inhibition at 1.4 uM {MMP8} {3} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {3}3Float%
94Inhibition at 0.46 uM {MMP8} {1} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {1}3Float%
95Inhibition at 0.46 uM {MMP8} {2} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {2}3Float%
96Inhibition at 0.46 uM {MMP8} {3} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {3}3Float%
97Inhibition at 0.15 uM {MMP8} {1} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {1}3Float%
98Inhibition at 0.15 uM {MMP8} {2} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {2}3Float%
99Inhibition at 0.15 uM {MMP8} {3} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {3}3Float%
100Inhibition at 0.051 uM {MMP8} {1} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {1}3Float%
101Inhibition at 0.051 uM {MMP8} {2} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {2}3Float%
102Inhibition at 0.051 uM {MMP8} {3} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {3}3Float%
103Inhibition at 0.017 uM {MMP8} {1} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {1}3Float%
104Inhibition at 0.017 uM {MMP8} {2} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {2}3Float%
105Inhibition at 0.017 uM {MMP8} {3} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {3}3Float%
106Inhibition at 0.0057 uM {MMP8} {1} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {1}3Float%
107Inhibition at 0.0057 uM {MMP8} {2} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {2}3Float%
108Inhibition at 0.0057 uM {MMP8} {3} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {3}3Float%
109Qualifier {MMP9}Inhibition Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.4String
110IC50 {MMP9}*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) molar.4FloatμM
111Top {MMP9}The maximal or asymptotic response above the baseline as concentration increases without bound.4Float
112Bottom {MMP9}Adjustable baseline of the curve fit, minimal response value.4Float
113Hill Slope {MMP9}The variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.4Float
114Inflection Point Concentration {MMP9}The concentration value for the inflection point of the curve.4FloatμM
115Inhibition at 112.5 uM {MMP9} {1} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {1}4Float%
116Inhibition at 112.5 uM {MMP9} {2} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {2}4Float%
117Inhibition at 112.5 uM {MMP9} {3} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {3}4Float%
118Inhibition at 37.5 uM {MMP9} {1} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {1}4Float%
119Inhibition at 37.5 uM {MMP9} {2} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {2}4Float%
120Inhibition at 37.5 uM {MMP9} {3} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {3}4Float%
121Inhibition at 12.5 uM {MMP9} {1} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {1}4Float%
122Inhibition at 12.5 uM {MMP9} {2} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {2}4Float%
123Inhibition at 12.5 uM {MMP9} {3} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {3}4Float%
124Inhibition at 4.2 uM {MMP9} {1} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {1}4Float%
125Inhibition at 4.2 uM {MMP9} {2} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {2}4Float%
126Inhibition at 4.2 uM {MMP9} {3} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {3}4Float%
127Inhibition at 1.4 uM {MMP9} {1} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {1}4Float%
128Inhibition at 1.4 uM {MMP9} {2} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {2}4Float%
129Inhibition at 1.4 uM {MMP9} {3} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {3}4Float%
130Inhibition at 0.46 uM {MMP9} {1} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {1}4Float%
131Inhibition at 0.46 uM {MMP9} {2} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {2}4Float%
132Inhibition at 0.46 uM {MMP9} {3} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {3}4Float%
133Inhibition at 0.15 uM {MMP9} {1} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {1}4Float%
134Inhibition at 0.15 uM {MMP9} {2} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {2}4Float%
135Inhibition at 0.15 uM {MMP9} {3} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {3}4Float%
136Inhibition at 0.051 uM {MMP9} {1} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {1}4Float%
137Inhibition at 0.051 uM {MMP9} {2} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {2}4Float%
138Inhibition at 0.051 uM {MMP9} {3} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {3}4Float%
139Inhibition at 0.017 uM {MMP9} {1} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {1}4Float%
140Inhibition at 0.017 uM {MMP9} {2} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {2}4Float%
141Inhibition at 0.017 uM {MMP9} {3} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {3}4Float%
142Inhibition at 0.0057 uM {MMP9} {1} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {1}4Float%
143Inhibition at 0.0057 uM {MMP9} {2} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {2}4Float%
144Inhibition at 0.0057 uM {MMP9} {3} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {3}4Float%
145Qualifier {MMP10}Inhibition Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.5String
146IC50 {MMP10}*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) molar.5FloatμM
147Top {MMP10}The maximal or asymptotic response above the baseline as concentration increases without bound.5Float
148Bottom {MMP10}Adjustable baseline of the curve fit, minimal response value.5Float
149Hill Slope {MMP10}The variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.5Float
150Inflection Point Concentration {MMP10}The concentration value for the inflection point of the curve.5FloatμM
151Inhibition at 112.5 uM {MMP10} {1} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {1}5Float%
152Inhibition at 112.5 uM {MMP10} {2} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {2}5Float%
153Inhibition at 112.5 uM {MMP10} {3} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {3}5Float%
154Inhibition at 37.5 uM {MMP10} {1} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {1}5Float%
155Inhibition at 37.5 uM {MMP10} {2} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {2}5Float%
156Inhibition at 37.5 uM {MMP10} {3} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {3}5Float%
157Inhibition at 12.5 uM {MMP10} {1} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {1}5Float%
158Inhibition at 12.5 uM {MMP10} {2} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {2}5Float%
159Inhibition at 12.5 uM {MMP10} {3} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {3}5Float%
160Inhibition at 4.2 uM {MMP10} {1} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {1}5Float%
161Inhibition at 4.2 uM {MMP10} {2} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {2}5Float%
162Inhibition at 4.2 uM {MMP10} {3} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {3}5Float%
163Inhibition at 1.4 uM {MMP10} {1} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {1}5Float%
164Inhibition at 1.4 uM {MMP10} {2} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {2}5Float%
165Inhibition at 1.4 uM {MMP10} {3} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {3}5Float%
166Inhibition at 0.46 uM {MMP10} {1} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {1}5Float%
167Inhibition at 0.46 uM {MMP10} {2} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {2}5Float%
168Inhibition at 0.46 uM {MMP10} {3} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {3}5Float%
169Inhibition at 0.15 uM {MMP10} {1} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {1}5Float%
170Inhibition at 0.15 uM {MMP10} {2} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {2}5Float%
171Inhibition at 0.15 uM {MMP10} {3} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {3}5Float%
172Inhibition at 0.051 uM {MMP10} {1} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {1}5Float%
173Inhibition at 0.051 uM {MMP10} {2} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {2}5Float%
174Inhibition at 0.051 uM {MMP10} {3} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {3}5Float%
175Inhibition at 0.017 uM {MMP10} {1} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {1}5Float%
176Inhibition at 0.017 uM {MMP10} {2} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {2}5Float%
177Inhibition at 0.017 uM {MMP10} {3} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {3}5Float%
178Inhibition at 0.0057 uM {MMP10} {1} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {1}5Float%
179Inhibition at 0.0057 uM {MMP10} {2} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {2}5Float%
180Inhibition at 0.0057 uM {MMP10} {3} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {3}5Float%
181Qualifier {MMP13}Inhibition Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.6String
182IC50 {MMP13}*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) molar.6FloatμM
183Top {MMP13}The maximal or asymptotic response above the baseline as concentration increases without bound.6Float
184Bottom {MMP13}Adjustable baseline of the curve fit, minimal response value.6Float
185Hill Slope {MMP13}The variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.6Float
186Inflection Point Concentration {MMP13}The concentration value for the inflection point of the curve.6FloatμM
187Inhibition at 112.5 uM {MMP13} {1} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {1}6Float%
188Inhibition at 112.5 uM {MMP13} {2} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {2}6Float%
189Inhibition at 112.5 uM {MMP13} {3} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {3}6Float%
190Inhibition at 37.5 uM {MMP13} {1} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {1}6Float%
191Inhibition at 37.5 uM {MMP13} {2} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {2}6Float%
192Inhibition at 37.5 uM {MMP13} {3} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {3}6Float%
193Inhibition at 12.5 uM {MMP13} {1} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {1}6Float%
194Inhibition at 12.5 uM {MMP13} {2} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {2}6Float%
195Inhibition at 12.5 uM {MMP13} {3} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {3}6Float%
196Inhibition at 4.2 uM {MMP13} {1} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {1}6Float%
197Inhibition at 4.2 uM {MMP13} {2} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {2}6Float%
198Inhibition at 4.2 uM {MMP13} {3} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {3}6Float%
199Inhibition at 1.4 uM {MMP13} {1} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {1}6Float%
200Inhibition at 1.4 uM {MMP13} {2} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {2}6Float%
201Inhibition at 1.4 uM {MMP13} {3} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {3}6Float%
202Inhibition at 0.46 uM {MMP13} {1} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {1}6Float%
203Inhibition at 0.46 uM {MMP13} {2} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {2}6Float%
204Inhibition at 0.46 uM {MMP13} {3} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {3}6Float%
205Inhibition at 0.15 uM {MMP13} {1} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {1}6Float%
206Inhibition at 0.15 uM {MMP13} {2} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {2}6Float%
207Inhibition at 0.15 uM {MMP13} {3} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {3}6Float%
208Inhibition at 0.051 uM {MMP13} {1} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {1}6Float%
209Inhibition at 0.051 uM {MMP13} {2} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {2}6Float%
210Inhibition at 0.051 uM {MMP13} {3} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {3}6Float%
211Inhibition at 0.017 uM {MMP13} {1} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {1}6Float%
212Inhibition at 0.017 uM {MMP13} {2} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {2}6Float%
213Inhibition at 0.017 uM {MMP13} {3} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {3}6Float%
214Inhibition at 0.0057 uM {MMP13} {1} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {1}6Float%
215Inhibition at 0.0057 uM {MMP13} {2} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {2}6Float%
216Inhibition at 0.0057 uM {MMP13} {3} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {3}6Float%
217Qualifier {MMP14}Inhibition Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.7String
218IC50 {MMP14}*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) molar.7FloatμM
219Top {MMP14}The maximal or asymptotic response above the baseline as concentration increases without bound.7Float
220Bottom {MMP14}Adjustable baseline of the curve fit, minimal response value.7Float
221Hill Slope {MMP14}The variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.7Float
222Inflection Point Concentration {MMP14}The concentration value for the inflection point of the curve.7FloatμM
223Inhibition at 112.5 uM {MMP14} {1} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {1}7Float%
224Inhibition at 112.5 uM {MMP14} {2} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {2}7Float%
225Inhibition at 112.5 uM {MMP14} {3} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {3}7Float%
226Inhibition at 37.5 uM {MMP14} {1} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {1}7Float%
227Inhibition at 37.5 uM {MMP14} {2} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {2}7Float%
228Inhibition at 37.5 uM {MMP14} {3} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {3}7Float%
229Inhibition at 12.5 uM {MMP14} {1} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {1}7Float%
230Inhibition at 12.5 uM {MMP14} {2} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {2}7Float%
231Inhibition at 12.5 uM {MMP14} {3} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {3}7Float%
232Inhibition at 4.2 uM {MMP14} {1} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {1}7Float%
233Inhibition at 4.2 uM {MMP14} {2} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {2}7Float%
234Inhibition at 4.2 uM {MMP14} {3} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {3}7Float%
235Inhibition at 1.4 uM {MMP14} {1} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {1}7Float%
236Inhibition at 1.4 uM {MMP14} {2} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {2}7Float%
237Inhibition at 1.4 uM {MMP14} {3} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {3}7Float%
238Inhibition at 0.46 uM {MMP14} {1} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {1}7Float%
239Inhibition at 0.46 uM {MMP14} {2} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {2}7Float%
240Inhibition at 0.46 uM {MMP14} {3} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {3}7Float%
241Inhibition at 0.15 uM {MMP14} {1} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {1}7Float%
242Inhibition at 0.15 uM {MMP14} {2} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {2}7Float%
243Inhibition at 0.15 uM {MMP14} {3} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {3}7Float%
244Inhibition at 0.051 uM {MMP14} {1} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {1}7Float%
245Inhibition at 0.051 uM {MMP14} {2} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {2}7Float%
246Inhibition at 0.051 uM {MMP14} {3} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {3}7Float%
247Inhibition at 0.017 uM {MMP14} {1} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {1}7Float%
248Inhibition at 0.017 uM {MMP14} {2} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {2}7Float%
249Inhibition at 0.017 uM {MMP14} {3} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {3}7Float%
250Inhibition at 0.0057 uM {MMP14} {1} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {1}7Float%
251Inhibition at 0.0057 uM {MMP14} {2} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {2}7Float%
252Inhibition at 0.0057 uM {MMP14} {3} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {3}7Float%
253Qualifier {Meprin A}Inhibition Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.8String
254IC50 {Meprin A}*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) molar.8FloatμM
255Top {Meprin A}The maximal or asymptotic response above the baseline as concentration increases without bound.8Float
256Bottom {Meprin A}Adjustable baseline of the curve fit, minimal response value.8Float
257Hill Slope {Meprin A}The variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.8Float
258Inflection Point Concentration {Meprin A}The concentration value for the inflection point of the curve.8FloatμM
259Inhibition at 112.5 uM {Meprin A} {1} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {1}8Float%
260Inhibition at 112.5 uM {Meprin A} {2} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {2}8Float%
261Inhibition at 112.5 uM {Meprin A} {3} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {3}8Float%
262Inhibition at 37.5 uM {Meprin A} {1} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {1}8Float%
263Inhibition at 37.5 uM {Meprin A} {2} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {2}8Float%
264Inhibition at 37.5 uM {Meprin A} {3} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {3}8Float%
265Inhibition at 12.5 uM {Meprin A} {1} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {1}8Float%
266Inhibition at 12.5 uM {Meprin A} {2} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {2}8Float%
267Inhibition at 12.5 uM {Meprin A} {3} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {3}8Float%
268Inhibition at 4.2 uM {Meprin A} {1} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {1}8Float%
269Inhibition at 4.2 uM {Meprin A} {2} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {2}8Float%
270Inhibition at 4.2 uM {Meprin A} {3} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {3}8Float%
271Inhibition at 1.4 uM {Meprin A} {1} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {1}8Float%
272Inhibition at 1.4 uM {Meprin A} {2} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {2}8Float%
273Inhibition at 1.4 uM {Meprin A} {3} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {3}8Float%
274Inhibition at 0.46 uM {Meprin A} {1} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {1}8Float%
275Inhibition at 0.46 uM {Meprin A} {2} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {2}8Float%
276Inhibition at 0.46 uM {Meprin A} {3} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {3}8Float%
277Inhibition at 0.15 uM {Meprin A} {1} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {1}8Float%
278Inhibition at 0.15 uM {Meprin A} {2} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {2}8Float%
279Inhibition at 0.15 uM {Meprin A} {3} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {3}8Float%
280Inhibition at 0.051 uM {Meprin A} {1} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {1}8Float%
281Inhibition at 0.051 uM {Meprin A} {2} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {2}8Float%
282Inhibition at 0.051 uM {Meprin A} {3} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {3}8Float%
283Inhibition at 0.017 uM {Meprin A} {1} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {1}8Float%
284Inhibition at 0.017 uM {Meprin A} {2} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {2}8Float%
285Inhibition at 0.017 uM {Meprin A} {3} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {3}8Float%
286Inhibition at 0.0057 uM {Meprin A} {1} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {1}8Float%
287Inhibition at 0.0057 uM {Meprin A} {2} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {2}8Float%
288Inhibition at 0.0057 uM {Meprin A} {3} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {3}8Float%
289Qualifier {Meprin B}Inhibition Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.9String
290IC50 {Meprin B}*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) molar.9FloatμM
291Top {Meprin B}The maximal or asymptotic response above the baseline as concentration increases without bound.9Float
292Bottom {Meprin B}Adjustable baseline of the curve fit, minimal response value.9Float
293Hill Slope {Meprin B}The variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.9Float
294Inflection Point Concentration {Meprin B}The concentration value for the inflection point of the curve.9FloatμM
295Inhibition at 112.5 uM {Meprin B} {1} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {1}9Float%
296Inhibition at 112.5 uM {Meprin B} {2} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {2}9Float%
297Inhibition at 112.5 uM {Meprin B} {3} (112.5μM**)Value of % inhibition at 112.5 uM compound concentration; replicate {3}9Float%
298Inhibition at 37.5 uM {Meprin B} {1} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {1}9Float%
299Inhibition at 37.5 uM {Meprin B} {2} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {2}9Float%
300Inhibition at 37.5 uM {Meprin B} {3} (37.5μM**)Value of % inhibition at 37.5 uM compound concentration; replicate {3}9Float%
301Inhibition at 12.5 uM {Meprin B} {1} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {1}9Float%
302Inhibition at 12.5 uM {Meprin B} {2} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {2}9Float%
303Inhibition at 12.5 uM {Meprin B} {3} (12.5μM**)Value of % inhibition at 12.5 uM compound concentration; replicate {3}9Float%
304Inhibition at 4.2 uM {Meprin B} {1} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {1}9Float%
305Inhibition at 4.2 uM {Meprin B} {2} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {2}9Float%
306Inhibition at 4.2 uM {Meprin B} {3} (4.2μM**)Value of % inhibition at 4.2 uM compound concentration; replicate {3}9Float%
307Inhibition at 1.4 uM {Meprin B} {1} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {1}9Float%
308Inhibition at 1.4 uM {Meprin B} {2} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {2}9Float%
309Inhibition at 1.4 uM {Meprin B} {3} (1.4μM**)Value of % inhibition at 1.4 uM compound concentration; replicate {3}9Float%
310Inhibition at 0.46 uM {Meprin B} {1} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {1}9Float%
311Inhibition at 0.46 uM {Meprin B} {2} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {2}9Float%
312Inhibition at 0.46 uM {Meprin B} {3} (0.46μM**)Value of % inhibition at 0.46 uM compound concentration; replicate {3}9Float%
313Inhibition at 0.15 uM {Meprin B} {1} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {1}9Float%
314Inhibition at 0.15 uM {Meprin B} {2} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {2}9Float%
315Inhibition at 0.15 uM {Meprin B} {3} (0.15μM**)Value of % inhibition at 0.15 uM compound concentration; replicate {3}9Float%
316Inhibition at 0.051 uM {Meprin B} {1} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {1}9Float%
317Inhibition at 0.051 uM {Meprin B} {2} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {2}9Float%
318Inhibition at 0.051 uM {Meprin B} {3} (0.051μM**)Value of % inhibition at 0.051 uM compound concentration; replicate {3}9Float%
319Inhibition at 0.017 uM {Meprin B} {1} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {1}9Float%
320Inhibition at 0.017 uM {Meprin B} {2} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {2}9Float%
321Inhibition at 0.017 uM {Meprin B} {3} (0.017μM**)Value of % inhibition at 0.017 uM compound concentration; replicate {3}9Float%
322Inhibition at 0.0057 uM {Meprin B} {1} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {1}9Float%
323Inhibition at 0.0057 uM {Meprin B} {2} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {2}9Float%
324Inhibition at 0.0057 uM {Meprin B} {3} (0.0057μM**)Value of % inhibition at 0.0057 uM compound concentration; replicate {3}9Float%

* Activity Concentration. ** Test Concentration. § Panel component ID.
Additional Information
Grant Number: 1 R03 DA033985-01

Classification
PageFrom: